Yubo International Biotech (YBGJ) Ratios
Yubo International Biotech Ratios
YBGJ's free cash flow for Q2 2026 was $-84.10K. For the 2026 fiscal year, YBGJ's free cash flow was increased by $3.00 and operating cash flow was $-84.10K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.24 | 0.14 | 0.30 | 0.38 | 1.49 |
| Quick Ratio | 0.23 | 0.14 | 0.17 | 0.32 | 1.44 |
| Cash Ratio | 0.00 | 0.00 | 0.01 | 0.01 | 1.08 |
| Solvency Ratio | -0.32 | -0.33 | -0.40 | -0.32 | -0.55 |
| Operating Cash Flow Ratio | -0.30 | -0.28 | 0.03 | -0.37 | 0.08 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -3.64 | 0.17 | -1.33 | 0.32 |
| Net Current Asset Value | $ -2.12M | $ -4.15M | $ -2.16M | $ -3.66M | $ 631.54K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.31 | 0.34 | 0.59 | 0.13 |
| Debt-to-Equity Ratio | -0.04 | -0.14 | -1.40 | -20.53 | 0.27 |
| Debt-to-Capital Ratio | -0.04 | -0.16 | 3.51 | 1.05 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | -2.23 | 1.07 | 0.00 |
| Financial Leverage Ratio | -0.43 | -0.45 | -4.15 | -34.96 | 2.09 |
| Debt Service Coverage Ratio | 3708.77 | -4.33 | -2.94 | -0.00 | -2.22 |
| Interest Coverage Ratio | 4887.64 | 0.00 | -5262.98 | -0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.09 | 0.07 | 0.05 | 0.01 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.01 | 3.64 | 0.00 |
| Net Debt to EBITDA | -0.07 | -0.26 | -0.66 | -1.75 | 1.53 |
| Profitability Margins | |||||
| Gross Profit Margin | 6.08% | -6030.98% | 50.49% | 65.95% | 91.56% |
| EBIT Margin | -883.76% | -57113.60% | -1155.72% | -123.99% | -52.58% |
| EBITDA Margin | -751.48% | -51831.24% | -1129.32% | -122.27% | -51.61% |
| Operating Profit Margin | -883.76% | -51006.31% | -1155.72% | -123.99% | -52.58% |
| Pretax Profit Margin | -883.94% | -57112.16% | -1155.50% | -123.95% | -52.58% |
| Net Profit Margin | -803.07% | -51161.47% | -1155.28% | -123.92% | -52.58% |
| Continuous Operations Profit Margin | -803.07% | -57112.16% | -1155.28% | -123.92% | -52.58% |
| Net Income Per EBT | 90.85% | 89.58% | 99.98% | 99.97% | 100.00% |
| EBT Per EBIT | 100.02% | 111.97% | 99.98% | 99.97% | 100.00% |
| Return on Assets (ROA) | -127.41% | -115.67% | -51.30% | -33.62% | -29.11% |
| Return on Equity (ROE) | 55.21% | 51.84% | 213.09% | 1175.33% | -60.96% |
| Return on Capital Employed (ROCE) | 61.09% | 55.54% | 688.98% | -85.85% | -60.96% |
| Return on Invested Capital (ROIC) | 57.84% | 56.24% | -535.25% | -60.19% | -48.00% |
| Return on Tangible Assets | -134.07% | -119.60% | -52.82% | -33.90% | -29.78% |
| Earnings Yield | -62.33% | -42.76% | -10.68% | -3.13% | -1.34% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.32 | 0.01 | 0.30 | 2.22 | 3.13 |
| Payables Turnover | 0.12 | 0.20 | 0.09 | 1.54 | 1.13 |
| Inventory Turnover | 5.25 | 5.76 | 0.16 | 2.58 | 1.70 |
| Fixed Asset Turnover | 1.10 | 0.01 | 0.07 | 0.37 | 3.43 |
| Asset Turnover | 0.16 | 0.00 | 0.04 | 0.27 | 0.55 |
| Working Capital Turnover Ratio | -0.04 | 0.00 | -0.06 | -2.26 | -2.62 |
| Cash Conversion Cycle | -1840.48 | 44814.11 | -400.64 | 68.05 | 7.76 |
| Days of Sales Outstanding | 1157.27 | 46531.29 | 1208.81 | 164.13 | 116.46 |
| Days of Inventory Outstanding | 69.50 | 63.40 | 2277.57 | 141.53 | 214.47 |
| Days of Payables Outstanding | 3067.25 | 1780.58 | 3887.02 | 237.60 | 323.17 |
| Operating Cycle | 1226.77 | 46594.69 | 3486.38 | 305.66 | 330.92 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | 0.00 | -0.01 | 0.00 |
| Free Cash Flow Per Share | -0.01 | -0.01 | 0.00 | -0.01 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | -421401.00 | 0.00 | 1.72 | -1.81 | 1.04 |
| Capital Expenditure Coverage Ratio | -421401.00 | 0.00 | 1.72 | -1.81 | 1.04 |
| Operating Cash Flow Coverage Ratio | -10.70 | -2.79 | 0.09 | -0.38 | 0.32 |
| Operating Cash Flow to Sales Ratio | -6.27 | -385.51 | 0.65 | -0.82 | 0.07 |
| Free Cash Flow Yield | -48.67% | -32.22% | 0.25% | -3.22% | 0.01% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.61 | -2.34 | -9.36 | -31.94 | -74.60 |
| Price-to-Sales (P/S) Ratio | 12.88 | 1196.55 | 108.15 | 39.58 | 39.22 |
| Price-to-Book (P/B) Ratio | -0.89 | -1.21 | -19.95 | -375.42 | 45.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.05 | -3.10 | 396.28 | -31.06 | 14592.81 |
| Price-to-Operating Cash Flow Ratio | -2.05 | -3.10 | 165.29 | -48.25 | 525.22 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.00 | 0.41 | -0.27 | 0.78 |
| Enterprise Value Multiple | -1.78 | -2.57 | -10.23 | -34.13 | -74.47 |
| Enterprise Value | 1.80M | 4.62M | 12.05M | 51.92M | 52.04M |
| EV to EBITDA | -1.78 | -2.57 | -10.23 | -34.13 | -74.47 |
| EV to Sales | 13.41 | 1332.50 | 115.56 | 41.72 | 38.43 |
| EV to Free Cash Flow | -2.14 | -3.46 | 423.41 | -32.75 | 14299.51 |
| EV to Operating Cash Flow | -2.14 | -3.46 | 176.61 | -50.86 | 514.66 |
| Tangible Book Value Per Share | -0.01 | -0.03 | -0.01 | -0.00 | 0.01 |
| Shareholders’ Equity Per Share | -0.01 | -0.03 | -0.00 | -0.00 | 0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.09 | 0.10 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 0.91 | 0.90 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 6.57 | 359.51 | 9.94 | 1.05 | 0.40 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.78 | 0.75 | -0.06 | 0.66 | -0.14 |
Currency in USD
